- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06441409
Effect of Lifestyle Intervention on Mobilization of Fat Storage and Iron Deposition in Obesity (MASLD)
Effect of Calorie-restricted Balanced Diet on Mobilization of Fat Storage Pools and Iron Deposition in Individuals With Obesity
The goal of this clinical trial is to learn if calorie-restricted balanced diet could uniquely influence various fat storage pools and iron deposition and explore the relationships between fat or iron deposition loss in specific locations and glucose metabolism. The main questions it aims to answer are:
After lifestyle intervention, which part of the body shows the fastest fat mobilization? Which part shows the slowest fat mobilization? Which area's fat mobilization is most related to the alleviation of glucose metabolism? Is there a relationship between the fat deposition in organs and the iron deposition in organs?
Researchers will compare the liver fat, pancreatic fat, visceral fat, subscutaneous fat, liver and pancrease iron depositon after lifestyle intervention using self pre-and post-control .
Participants will:
Receive the lifestyle intervention in outpatient. Visit the clinic once after 6 months for checkups and tests. Keep a diary of their diet.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410013
- The third xiangya hospital of Central South University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age between 18 and 70 years
- have a BMI greater than 28.0 kg/m2
- exhibit abdominal obesity, defined as a waist circumference of at least 90 cm for men and 85 cm for women
- willing to undergo a 6-month lifestyle intervention
Exclusion Criteria:
- For newly diagnosed patients with type 2 diabetes: those with fasting blood glucose ≥ 11.1 mmol/L, random blood glucose ≥ 16.7 mmol/L, or HbA1c ≥ 9.0%, or those exhibiting significant hyperglycemic symptoms, who need to start antidiabetic medication treatment immediately;
- a prior history of pancreatic diseases;
- combination of drug-induced hepatitis, autoimmune hepatitis, and viral hepatitis;
- with a definitive diagnosis of diabetes who have already started medication treatment;
- severe complications from type 2 diabetes or other significant diseases;
- usage of drugs affecting body weight, insulin sensitivity, or metabolic-associated fatty liver disease in the past three months (such as insulin, glucocorticoids, thiazolidinediones, metformin, SGLT-2 inhibitors, or GLP-1 receptor agonists);
- with malignant tumors;
- acute or chronic infection;
- with elevated transaminase levels of unknown cause;
- hemochromatosis;
- with iron deficiency anemia who are receiving iron supplementation;
- who have donated blood or received a transfusion within the past six months;
- who have experienced cardiovascular events within the past six months;
- with acute or chronic blood loss;
- alcohol dependence, defined as ethanol intake exceeding 140 g/week for men and 70 g/week for women;
- pregnant and lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: lifestyle intervention
Patients were intervened with lifestyle only and returned to clinic for tests in 6 months. Lifestyle intervention included the diet and exercise. Diet was an energy-restricted balanced diet. Exercise requires 5 days a week and 30 minutes every day. |
Patients were intervened with lifestyle only and returned to clinic for tests in 6 months. Lifestyle intervention included the diet and exercise. Diet was an energy-restricted balanced diet. Exercise requires 5 days a week and 30 minutes every day. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The site-specific fat mobilization after 6 months' lifestyle intervention.
Time Frame: After 6 months intervention, patients were return to hospital for MRI analysis.
|
Defined by percentage MRI-based fat loss.
Calculated as (initial measurement minus follow-up measurement) / (initial measurement) × 100 and predefined to be assessed at 6-month follow-up.
MRI scans were acquired with an INGENIA ELITION X (Philips Medical Systems Nederland B.V.).
|
After 6 months intervention, patients were return to hospital for MRI analysis.
|
|
The site-specific iron deposition mobilization after 6 months' lifestyle intervention.
Time Frame: Patients were return to hospital for MRI and serum tests after lifestyle intervention for 6 months.
|
Defined by percentage MRI-based organ iron content loss.
Calculated as (initial measurement minus follow-up measurement) / (initial measurement) × 100 and predefined to be assessed at 6-month follow-up.
MRI scans were acquired with an INGENIA ELITION X (Philips Medical Systems Nederland B.V.).
|
Patients were return to hospital for MRI and serum tests after lifestyle intervention for 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The correlation between liver fat and liver iron.
Time Frame: Patients were return to hospital for MRI and serum tests after lifestyle intervention for 6 months.
|
Categorical variables were summarized as numbers (percentages), continuous variables with normal distributions as means (SDs), and continuous variables with non-normal distributions as medians (interquartile ranges [IQRs]).
Treatment-induced changes were tested by the paired t test and Wilcoxon signed-rank test, as appropriate.
The unpaired t test, Mann-Whitney U test, and Kruskal-Wallis test were used for group comparisons.
Correlations between site-specific fat mobilization and clinical outcomes were investigated by calculating Pearson correlation coefficients and Pearson partial correlation coefficients.
Two-sided P < 0.05 was considered statistically significant.
Statistical analyses were performed using R software version 4.1.2
(http://www.r-project.org/).
|
Patients were return to hospital for MRI and serum tests after lifestyle intervention for 6 months.
|
Collaborators and Investigators
Investigators
- Study Chair: Ping Jin, The third xiangya hospital of Central South University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22218
- No. 2022JJ40749 (Other Grant/Funding Number: the Natural Science Foundation of Hunan Province)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Fat
-
University of Eastern FinlandKuopio University HospitalCompleted
-
University of OxfordCompletedNAFLD | Fat; LiverUnited Kingdom
-
University of Wisconsin, MadisonNational Institute for Biomedical Imaging and Bioengineering (NIBIB)RecruitingHealthy | Iron Overload | Liver FatUnited States
-
Wageningen UniversityCompletedNonalcoholic Fatty Liver Disease | Hepatic Fat AccumulationNetherlands
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Istanbul Gelisim UniversityMarmara UniversityCompletedObesity | Liver Fat | Fatty Liver DiseaseTurkey
-
Massachusetts General HospitalRecruitingFatty Liver | Liver Fat | Non-Alcoholic Fatty Liver Disease | Intermittent Fasting | Fatty Liver, NonalcoholicUnited States
-
Yonsei UniversityCompleted
-
Protein Supplies SLCompleted
-
Aaron FensterCompletedDetermine the Number of Anatomical Sites at Which Successful Thermoacoustic Fat Measurements Can be Made From Five Acquisitions Using the FLIP ITA Device | Determine the Correlation of Fat Measures Obtained by the FLIP Device and Those Obtained From Quantitative MRI | Provide Insight...Canada
Clinical Trials on Lifestyle intervention
-
Sheba Medical CenterD-Cure, Israel; Chief Scientist, The Israel Ministry of ScienceCompleted
-
Fundación para la Lucha contra las Enfermedades...Alzheimer's AssociationCompletedAlzheimer DiseaseChile, Brazil, Argentina, Bolivia, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Peru, Puerto Rico, Uruguay
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHyperglycemia | Glucose Metabolism Disorders | Metabolic Diseases | Obesity | Diabetes Mellitus | Endocrine System Diseases | Overnutrition | Nutrition Disorders | Overweight | Body Weight | Signs and SymptomsUnited States
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Michael... and other collaboratorsCompleted
-
Molde University CollegeNorwegian Labour and Welfare AdministrationCompletedObesity | Morbid Obesity | Work Related Illnesses | Life Style | Sick-leave
-
Karolinska InstitutetNot yet recruitingDepression | Anxiety | Mental Health Disorder | Psychological Distress
-
Mayo ClinicCompletedObesityUnited States
-
Laval UniversityActive, not recruitingPhysical Activity | Weight Loss | Dietary Modification | BreastfeedingCanada
-
University of AdelaideCompletedInsulin Resistance | Type 2 DiabetesAustralia
-
Umeå UniversityActive, not recruitingHypertension,Essential | Lifestyle-related ConditionSweden